SGP SpyGlass Pharma

SpyGlass Pharma Acquires AVS from Santen to Secure IOL Manufacturing for BIM-IOL System

SpyGlass Pharma acquired 100% of Advanced Vision Science, Inc. (AVS), its current IOL manufacturer and a former Santen subsidiary, for ~$13M. The deal secures scalable commercial manufacturing capacity for the Phase 3 BIM-IOL System and accelerates development of premium lens options (toric, EDOF) integrated with its drug-delivery platform. AVS will continue supplying Santen in Japan and licensing material to Bausch + Lomb and others.

SpyGlass: Phase 3 BIM-IOL enrollment on track for 2027 completion

The 8-K confirms that the two parallel registrational Phase 3 trials of the BIM-IOL System remain on track, with enrollment completion now guided for 2027. The company also states that the first-in-human trial of the next-generation BIM-DRS is expected to start in the second half of 2026. No new regulatory filings or agency decisions are reported.

SpyGlass Pharma reports positive 12-month Phase 1/2 topline for BIM-IOL System

The Phase 1/2 trial met its key efficacy endpoints, showing 34-42% IOP reduction and 96-98% medication-free rates at 12 months. Vision outcomes matched state-of-the-art monofocal IOLs, with 100% achieving 20/32 or better BCDVA. Safety profile was comparable to routine cataract surgery, supporting advancement to Phase 3.